 The first six months of 2021 have been transformational for 4D Pharma PLC, the developer of live biotherapeutic drugs that interact with the human microbiome. The key milestone, certainly from a capital markets perspective, was the companys Nasdaq listing in March via special acquisition vehicle, which now provides a significantly larger investor base. 